

EMA/101137/2024

European Medicines Agency decision P/0081/2024

of 15 March 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cannabidiol, (EMA-003176-PIP02-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0081/2024

of 15 March 2024

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for cannabidiol, (EMA-003176-PIP02-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Zynerva Pharmaceuticals, Inc. on 21 November 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 February 2024, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for cannabidiol, gel, transdermal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for cannabidiol, gel, transdermal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for cannabidiol, gel, transdermal use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Zynerva Pharmaceuticals Inc, 80 W. Lancaster Ave., Suite 300, 19333 - Devon, PA, United States.

EMA/PDCO/536771/2023
Amsterdam, 23 February 2024

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003176-PIP02-22

Scope of the application

Active substance(s):

Cannabidiol

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of fragile X syndrome

Pharmaceutical form(s):

Gel

Route(s) of administration:

Transdermal use

Name/corporate name of the PIP applicant:

Zynerba Pharmaceuticals, Inc.

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Zynerba Pharmaceuticals, Inc. submitted for agreement to the European Medicines Agency on 21 November 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 3 January 2023.

Supplementary information was provided by the applicant on 17 November 2023. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of fragile X syndrome

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- gel, transdermal use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of fragile X syndrome

2.1.1. Indication(s) targeted by the PIP

Treatment of fragile X syndrome

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Gel

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable.
Non-clinical studies	Study 1 (ZYN2-NC-34) Definitive juvenile toxicity study to evaluate safety of cannabidiol administered as transdermal gel in children from 3 years of age.
Clinical studies	Study 2 (ZYN2-CL-009) Open-label, multi-centre study to assess safety and efficacy of cannabidiol administered as a transdermal gel for the treatment of children and adolescents from 6 years to less than 18 years of age with fragile X syndrome.

	Study 3 (ZYN2-CL-016) Randomized, double-blind, placebo-controlled, multi-centre study to assess the efficacy and safety of cannabidiol administered as a transdermal gel for treatment of children and adolescent patients from 3 years to less than 18 years of age with fragile X syndrome. Study 4 (ZYN2-CL-017) Open-label extension study to assess the long-term safety and tolerability of cannabidiol administered as a transdermal gel to children, adolescents from 3 years to less than 18 years of age (and adults) with fragile X syndrome. Study 5 (ZYN2-CL-033) Randomized, double-blind, placebo-controlled, multi-centre, study to evaluate efficacy and safety of cannabidiol administered as a transdermal gel to children and adolescents from 3 years to less than 18 years of age (and adults) with fragile X syndrome. Study 6 Randomized, double-blind, placebo-controlled, multi-centre, study to evaluate efficacy and safety of cannabidiol administered as a transdermal gel to children and adolescents from 3 years to less than 18 years of age (and adults) with fragile X syndrome.
Modelling and simulation analyses	Study 7 (ZYN2-CL-015) Modelling and simulation population PK analysis to evaluate the use of the product in fragile X syndrome in children from 3 years to less than 18 years of age.
Other studies	Not applicable.
Extrapolation plan	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.